 |
|
Personality Change During Depression TreatmentA Placebo-Controlled Trial
Tony Z. Tang, PhD;
Robert J. DeRubeis, PhD;
Steven D. Hollon, PhD;
Jay Amsterdam, MD;
Richard Shelton, MD;
Benjamin Schalet, MA
Arch Gen Psychiatry. 2009;66(12):1322-1330.
Context High neuroticism is a personality risk factor that reflects much of the genetic vulnerability to major depressive disorder (MDD), and low extraversion may increase risk as well. Both have been linked to the serotonin system.
Objectives To test whether patients with MDD taking selective serotonin reuptake inhibitors (SSRIs) report greater changes in neuroticism and extraversion than patients receiving inert placebo, and to examine the state effect hypothesis that self-reported personality change during SSRI treatment is merely a change of depression-related measurement bias.
Design A placebo-controlled trial.
Setting Research clinics.
Patients Adult patients with moderate to severe MDD randomized to receive paroxetine (n = 120), placebo (n = 60), or cognitive therapy (n = 60).
Outcome Measures NEO Five-Factor Inventory and Hamilton Rating Scale for Depression.
Results Patients who took paroxetine reported greater personality change than placebo patients, even after controlling for depression improvement (neuroticism, P < .001; extraversion, P = .002). The advantage of paroxetine over placebo in antidepressant efficacy was no longer significant after controlling for change in neuroticism (P = .46) or extraversion (P = .14). Patients taking paroxetine reported 6.8 times as much change on neuroticism and 3.5 times as much change on extraversion as placebo patients matched for depression improvement. Although placebo patients exhibited substantial depression improvement (Hamilton Rating Scale for Depression score, –1.2 SD, P < .001), they reported little change on neuroticism (–0.18 SD, P = .08) or extraversion (0.08 SD, P = .50). Cognitive therapy produced greater personality change than placebo (P  .01); but its advantage on neuroticism was no longer significant after controlling for depression (P = .14). Neuroticism reduction during treatment predicted lower relapse rates among paroxetine responders (P = .003) but not among cognitive therapy responders (P = .86).
Conclusions Paroxetine appears to have a specific pharmacological effect on personality that is distinct from its effect on depression. If replicated, this pattern would disconfirm the state effect hypothesis and instead support the notion that SSRIs' effects on personality go beyond and perhaps contribute to their antidepressant effects.
Author Affiliations: Northwestern University, Evanston, Illinois (Dr Tang and Mr Schalet); University of Pennsylvania, Philadelphia (Drs DeRubeis and Amsterdam); and Vanderbilt University, Nashville, Tennessee (Drs Hollon and Shelton).
 CiteULike  Connotea  Delicious  Digg  Facebook  Reddit  Technorati  Twitter
What's this?
RELATED ARTICLE
This Month in Archives of General Psychiatry
Arch Gen Psychiatry. 2009;66(12):1285.
FULL TEXT
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
A Dimensional-Spectrum Model of Psychopathology: Progress and Opportunities
Krueger and Markon
Arch Gen Psychiatry 2011;68:10-11.
FULL TEXT
Inflammation, Sanitation, and Consternation: Loss of Contact With Coevolved, Tolerogenic Microorganisms and the Pathophysiology and Treatment of Major Depression
Raison et al.
Arch Gen Psychiatry 2010;67:1211-1224.
ABSTRACT
| FULL TEXT
Economic Costs of Neuroticism: A Population-Based Study
Cuijpers et al.
Arch Gen Psychiatry 2010;67:1086-1093.
ABSTRACT
| FULL TEXT
Depression Severity and Effect of Antidepressant Medications--Reply
DeRubeis et al.
JAMA 2010;303:1599-1599.
FULL TEXT
RAPID RESPONSES TO THIS ARTICLE
The Wrong Placebo was Used
Pesach Lichtenberg
Arch Gen Psychiatry Online, 23 Feb 2010.
TEXT
|
